Natera (NASDAQ:NTRA – Get Free Report) had its target price hoisted by analysts at JPMorgan Chase & Co. from $360.00 to $460.00 in a research report issued to clients and investors on Wednesday, Benzinga reports. The firm presently has an “overweight” rating on the medical research company’s stock. JPMorgan Chase & Co.‘s price target points to a potential upside of 16.53% from the stock’s current price.
Several other research firms have also recently weighed in on NTRA. BTIG Research raised their price objective on shares of Natera from $290.00 to $320.00 and gave the company a “buy” rating in a research report on Friday, August 7th. Barclays upped their target price on shares of Natera from $340.00 to $475.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 7th. Royal Bank Of Canada upped their target price on shares of Natera from $350.00 to $460.00 and gave the stock an “outperform” rating in a research report on Friday, September 25th. Rothschild & Co Redburn began coverage on Natera in a research note on Tuesday, September 8th. They issued a “buy” rating and a $385.00 target price on the stock. Finally, Guggenheim raised their price target on Natera from $360.00 to $475.00 and gave the company a “buy” rating in a research report on Thursday, October 1st. Two research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $368.69.
Check Out Our Latest Report on NTRA
Natera Stock Down 0.2%
Natera (NASDAQ:NTRA – Get Free Report) last posted its earnings results on Thursday, August 6th. The medical research company reported ($0.47) EPS for the quarter, topping the consensus estimate of ($0.49) by $0.02. Natera had a negative return on equity of 11.38% and a negative net margin of 7.11%. The business had revenue of $752.75 million during the quarter, compared to analysts’ expectations of $661.24 million. During the same period in the previous year, the business earned ($0.74) earnings per share. The firm’s revenue was up 37.7% on a year-over-year basis. Research analysts expect that Natera will post -1.02 EPS for the current year.
Insider Buying and Selling at Natera
In other Natera news, insider Solomon Moshkevich sold 15,160 shares of the company’s stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $326.89, for a total transaction of $4,955,652.40. Following the completion of the sale, the insider directly owned 110,859 shares in the company, valued at $36,238,698.51. This represents a 12.03% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Steven Chapman sold 3,580 shares of the company’s stock in a transaction dated Tuesday, July 28th. The shares were sold at an average price of $254.07, for a total transaction of $909,570.60. Following the sale, the chief executive officer owned 102,973 shares of the company’s stock, valued at approximately $26,162,350.11. The trade was a 3.36% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 52,985 shares of company stock worth $16,119,137 in the last 90 days. 5.05% of the stock is owned by company insiders.
Institutional Investors Weigh In On Natera
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Versant Capital Management Inc grew its holdings in shares of Natera by 4.6% in the third quarter. Versant Capital Management Inc now owns 815 shares of the medical research company’s stock worth $337,000 after purchasing an additional 36 shares during the last quarter. Parallel Advisors LLC increased its stake in shares of Natera by 5.5% in the first quarter. Parallel Advisors LLC now owns 905 shares of the medical research company’s stock worth $181,000 after buying an additional 47 shares during the period. Raiffeisen Bank International AG raised its holdings in Natera by 48.5% during the 2nd quarter. Raiffeisen Bank International AG now owns 150 shares of the medical research company’s stock valued at $41,000 after buying an additional 49 shares during the last quarter. First Horizon Corp raised its holdings in Natera by 5.5% during the 1st quarter. First Horizon Corp now owns 982 shares of the medical research company’s stock valued at $196,000 after buying an additional 51 shares during the last quarter. Finally, Kestra Private Wealth Services LLC raised its holdings in Natera by 5.3% during the 1st quarter. Kestra Private Wealth Services LLC now owns 1,246 shares of the medical research company’s stock valued at $249,000 after buying an additional 63 shares during the last quarter. Institutional investors own 99.90% of the company’s stock.
About Natera
Natera, Inc is a diagnostics company that develops and commercializes molecular testing services designed to assess genetic and disease-related risks. The company uses technologies including cell-free DNA analysis and next-generation sequencing to support clinical decision-making in reproductive health, oncology and organ transplantation.
Its reproductive health offerings include Panorama, a noninvasive prenatal test that screens for certain chromosomal conditions, and Horizon, a carrier screening test that evaluates whether prospective parents carry genetic variants associated with inherited disorders.
Further Reading
- Five stocks we like better than Natera
- Tesla Wants to Make Its Own Chips—What Could Go Wrong?
- IREN Limited’s AI Pivot Gains Traction—But Can Its Data Centers Deliver?
- PBF Energy’s Stunning Rally Faces a Critical Test
- Citi Stock Falls Despite Earnings Beat: What Investors Need to Know
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.
